StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Up 1.8 %
LPCN opened at $5.01 on Friday. The company has a 50 day moving average of $4.69 and a two-hundred day moving average of $3.67. Lipocine has a 52-week low of $2.31 and a 52-week high of $7.15. The company has a market cap of $26.80 million, a P/E ratio of -1.64 and a beta of 1.11.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.11. The company had revenue of $0.22 million during the quarter. Research analysts anticipate that Lipocine will post -1.49 earnings per share for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- Breakout Stocks: What They Are and How to Identify Them
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is a buyback in stocks? A comprehensive guide for investors
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Canadian Penny Stocks: Can They Make You Rich?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
